Viking Therapeutics, Inc. (VKTX) Financials

VKTX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 521.9 million 113.6 million
March 31, 2026 608.2 million 106.3 million
Dec. 31, 2025 715.7 million 76.7 million
Sept. 30, 2025 739.4 million 26.4 million

VKTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -125.2 million 11.1 million
March 31, 2026 -114.0 million 10.3 million
Dec. 31, 2025 -85.3 million 8.6 million
Sept. 30, 2025 -94.0 million 7.3 million

VKTX Net Income

No data available :(

VKTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 501.7 million - 4.1 million
March 31, 2026 603.0 million - -
Dec. 31, 2025 705.7 million - 137000
Sept. 30, 2025 714.6 million - 755000

VKTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 115.9 million
March 31, 2026 115.6 million
Dec. 31, 2025 114.0 million
Sept. 30, 2025 112.3 million

VKTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 115.8 million 16.8 million -
March 31, 2026 - 150.2 million 14.0 million -
Dec. 31, 2025 - 153.5 million 11.3 million -
Sept. 30, 2025 - 90.0 million 8.6 million -

VKTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - 94000
Sept. 30, 2025 - 114000

VKTX

Price: $32.98

52 week price:
22.96
43.15

Earnings Per Share: -4.67 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.7 million

Ebitda: -4.7 million

Market Capitalization: 3.9 billion

Links: